Stockreport

Candel Therapeutics stock up 172% after Phase III prostate cancer success [Yahoo! Finance]

Candel Therapeutics, Inc.  (CADL) 
PDF Researchers from the Massachusetts-based clinical-stage biopharma have announced that CAN-2409, designed as a multimodal biological immunotherapy candidate aimed at pro [Read more]